LYNX: DaraKd for the treatment of RRMM with prior Dara exposure

Results from the randomized phase II LYNX (NCT03871829) study comparing subcutaneous daratumumab + carfilzomib + dexamethasone (DaraKd) vs carfilzomib + dexamethasone (Kd) in 82 patients with relapsed/refractory multiple myeloma (RRMM) who received previous treatment with daratumumab were recently published in Leukemia & Lymphoma by Bahlis et al.

Key data: At a median follow-up of 16.8 months, no significant differences in rates of very good partial response or better were found between treatment groups (DaraKd, 45.5%; Kd, 40.9%; odds ratio, 1.20; 90% confidence interval [CI], 0.59–2.46; p = 0.68). At data cutoff, median progression-free survival (PFS) was comparable (DaraKd, 10.7 months; Kd, 10.6 months; hazard ratio, 0.79; 90% CI, 0.49–1.28; p = 0.42). No new safety concerns were identified.

Key learning: Daratumumab retreatment with DaraKd did not demonstrate significant benefit over Kd alone in patients with RRMM and prior daratumumab exposure, though the study was limited by slow enrollment and early termination. Future studies are needed to optimize daratumumab-based regimens for this patient population.